Clinical Trial SuccessCG highlighted their recent data with lead asset, cretostmogene, which resulted in a 46% 12-month complete response rate and showed no Grade 3+ treatment-related adverse events and no treatment-related discontinuations.
Growth PotentialCreto's potential to tap into BCG-naïve in high-risk and intermediate-risk populations is not yet fully reflected in the stock, suggesting expansion opportunities could propel Creto as a key option for NMIBC.
Regulatory ProgressCG Oncology reiterated guidance to initiate the BLA submission, aiming for the broadest label for creto at launch.